Seven Eight Capital LP Has $2.22 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Seven Eight Capital LP raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 3.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,556 shares of the biopharmaceutical company’s stock after purchasing an additional 1,650 shares during the quarter. Seven Eight Capital LP owned 0.06% of Ultragenyx Pharmaceutical worth $2,220,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Ultragenyx Pharmaceutical by 513.8% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock valued at $23,677,000 after acquiring an additional 424,476 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 13.3% during the 4th quarter. Franklin Resources Inc. now owns 214,738 shares of the biopharmaceutical company’s stock valued at $10,269,000 after acquiring an additional 25,144 shares in the last quarter. Rafferty Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 21.2% during the 4th quarter. Rafferty Asset Management LLC now owns 221,910 shares of the biopharmaceutical company’s stock valued at $10,612,000 after acquiring an additional 38,859 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Ultragenyx Pharmaceutical by 37.0% during the 4th quarter. New York State Common Retirement Fund now owns 72,866 shares of the biopharmaceutical company’s stock valued at $3,484,000 after acquiring an additional 19,673 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its holdings in shares of Ultragenyx Pharmaceutical by 42.5% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 57,000 shares of the biopharmaceutical company’s stock valued at $2,745,000 after acquiring an additional 17,000 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on RARE shares. Canaccord Genuity Group reissued a “buy” rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Stifel Nicolaus raised their price objective on Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a report on Friday, May 31st. TD Cowen raised their target price on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and raised their target price for the stock from $56.00 to $67.00 in a research report on Thursday, June 6th. Finally, Robert W. Baird raised their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a research report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $86.50.

Ultragenyx Pharmaceutical Trading Up 1.6 %

Ultragenyx Pharmaceutical stock traded up $0.72 during midday trading on Tuesday, reaching $45.18. The stock had a trading volume of 631,943 shares, compared to its average volume of 812,872. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $54.56. The company has a market capitalization of $3.76 billion, a P/E ratio of -5.66 and a beta of 0.56. The company has a fifty day moving average price of $41.20 and a two-hundred day moving average price of $44.54.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The firm had revenue of $108.83 million during the quarter, compared to the consensus estimate of $116.03 million. During the same period in the previous year, the firm earned ($2.33) earnings per share. The business’s quarterly revenue was up 8.3% on a year-over-year basis. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.45 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $41.10, for a total value of $71,390.70. Following the completion of the sale, the director now directly owns 7,248 shares of the company’s stock, valued at approximately $297,892.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $41.10, for a total transaction of $71,390.70. Following the completion of the transaction, the director now owns 7,248 shares in the company, valued at approximately $297,892.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Karah Herdman Parschauer sold 9,806 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the transaction, the executive vice president now owns 57,981 shares of the company’s stock, valued at approximately $2,609,145. The disclosure for this sale can be found here. Insiders sold 12,127 shares of company stock valued at $536,593 in the last three months. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.